Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of nivolumab at a fixed dose across all of the PD-1 inhibitor’s monotherapy indications.
Related Videos
Related Content
